Skip to main content
logo
TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
1.545
-0.085 (-5.21%)
Nov 3, 2026, 11:22 AM EST - Market open

TransCode Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
26624832
Market Cap Growth
154.70%166.92%-43.27%-51.10%-73.50%-
Enterprise Value
1831-3-09
Last Close Price
1.636.8394.366091.00497486.691877587.23

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
0.190.04-1.162.522.611.56
P/TBV Ratio
---2.522.611.56

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.01--0.020.28--
Net Debt / Equity Ratio
-0.06-0.122.86-1.41-1.54-1.02
Net Debt / EBITDA Ratio
0.310.930.370.120.273.41
Net Debt / FCF Ratio
0.340.910.430.130.313.77
Quick Ratio
1.555.372.100.791.158.22
Current Ratio
1.976.292.561.281.708.97
Return on Equity (ROE)
-59.28%-46.26%--759.85%-148.57%-80.53%
Return on Assets (ROA)
-19.90%-14.14%-157.06%-190.26%-76.30%-32.05%
Return on Capital Employed (ROCE)
-17.40%-12.10%-346.30%-1156.50%-575.00%-30.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-3305.93%-553.44%-714.09%-448.43%-207.69%-21.44%
FCF Yield
-84.53%-311.72%-569.30%-437.89%-187.57%-17.30%
Buyback Yield / Dilution
-246.69%-5392.22%----
SEC Filings: 10-K · 10-Q